title: Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
abstract: BACKGROUND
  The purpose of this study was to investigate expression differences of p53, PTEN, PI3K, Akt and mTOR according to the human papillomavirus (HPV) infection and to evaluate clinical significance as prognostic markers in patients with locally advanced tonsillar cancer.
  
  
  METHODS
  Sixty-five patients were reviewed. Tissue microarrays were prepared from surgical specimens and stained with antibodies against p53, PTEN, PIK3CA, Akt and mTOR.
  
  
  RESULTS
  Twenty-six patients were HPV-positive. Expression of P53 as well as PIK3CA, Akt and mTOR were not significantly different between the 2 groups. However, total PTEN (nuclear and cytoplasmic PTEN) expression was significantly frequent in HPV-positive group. Both overall survival (OS) and disease-free survival (DFS) were significantly different between the 2 groups. Nuclear PTEN expression in the cancer area and pathological nodal stage were significantly correlated with DFS.
  
  
  CONCLUSIONS
  Our study suggests that the presence of PTEN expression with predisposition to nucleus more frequently observed in HPV-positive tonsillar cancers are significantly associated with favorable survival outcome, independent of activated PI3K/Akt/mTOR cell survival pathway.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea.
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Chun
authors.forename: Chan-Kwon
authors.initials: CK
authors.lastname: Jung
authors.forename: Hye Sung
authors.initials: HS
authors.lastname: Won
authors.forename: Jin-Hyoung
authors.initials: JH
authors.lastname: Kang
authors.forename: Yeon-Sil
authors.initials: YS
authors.lastname: Kim
authors.forename: Min-Sik
authors.initials: MS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis*; D058534:Class I Phosphatidylinositol 3-Kinases; D015331:Cohort Studies; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D051058:Oncogene Protein v-akt / Q000235:genetics / Q000378:metabolism*; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D030361:Papillomavirus Infections / Q000235:genetics / Q000401:mortality / Q000473:pathology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D015398:Signal Transduction; D016019:Survival Analysis; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D014067:Tonsillar Neoplasms / Q000235:genetics / Q000401:mortality / Q000821:virology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D058534:Class I Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D058570:TOR Serine-Threonine Kinases; D016159:Tumor Suppressor Protein p53; C546842:MTOR protein, human; C484760:PIK3CA protein, human; C494929:PTEN protein, human
keywords: P53; PI3K/Akt/mTOR pathway; PTEN; human papillomavirus (HPV); tonsillar cancer